Skip to main content
Premium Trial:

Request an Annual Quote

Medvet to Distribute Agendia's MammaPrint Test in Australia

NEW YORK (GenomeWeb News) - Medvet Science will distribute Agendia’s MammaPrint breast cancer prognosis test to hospitals in Australia, Agendia said today.
 
The Dutch company said its microarray-based test was developed from a 70-gene tumor expression profile that predicts disease outcome, and will be used by physicians to help plan follow-up therapy. 
 
Agendia CEO Bernhard Sixt said the Australia agreement is part of the company’s planned global expansion for the test. Medvet also has agreements in place with companies to market the test in South America, the UK, and South Africa. 
 
The test may “reduce consequences and associated costs of post-operative treatment,” said Greg Johansen, general manager of Adelaide-based Medvet.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.